ChartMill assigns a Buy % Consensus number of 80% to SURG. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-03 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-06-16 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-04-22 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-12-16 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-09-11 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-06-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-04-01 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-03-13 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-02-28 | Maxim Group | Initiate | Buy |
| 2022-01-24 | Ascendiant Capital | Initiate | Buy |
8 analysts have analysed SURG and the average price target is 9.69 USD. This implies a price increase of 463.37% is expected in the next year compared to the current price of 1.72.
The consensus rating for SURGEPAYS INC (SURG) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering SURGEPAYS INC (SURG) is 8.